Trials / Unknown
UnknownNCT01149902
Study of Chemo-Immunotherapy in Head and Neck Cancer Patients
Phase I Study of Chemo-Immunotherapy in Patients With Relapsed and Refractory Head and Neck Squamous Cell Carcinoma
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 10 (estimated)
- Sponsor
- University of Yamanashi · Academic / Other
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine safety and feasibility of Chemo-Immunotherapy using cyclophosphamide, docetaxel, OK-432, and autologous immature dendritic cells for patients with relapsed and refractory head and neck squamous cell carcinoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Cyclophosphamide, Docetaxel, Dendritic cells, OK-432 | Cyclophosphamide 50mg/day, day1-7 and 22-28 Docetaxel 30mg/m2, day6 and 27 OK-432 5KE/day, day7,14,28,35 |
Timeline
- Start date
- 2010-07-01
- Primary completion
- 2012-03-01
- First posted
- 2010-06-24
- Last updated
- 2011-08-24
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT01149902. Inclusion in this directory is not an endorsement.